Mohammed Salah Ayoup*ab,
Islam Shawkib,
Hamida Abdel-Hamidb,
Doaa A. Ghareebcg,
Aliaa Masoudc,
Marwa F. Harrasd,
Mohamed El-Atawy*be,
Nuha Salamah Alharbif and
Magda M. F. Ismaild
aDepartment of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia. E-mail: mayoup@kfu.edu.sa; mohammedsalahayoup@gmail.com
bDepartment of Chemistry, Faculty of Science, Alexandria University, Alexandria, Egypt. E-mail: mohamed.elatawi@alexu.edu.eg
cBio-Screening and Preclinical Trial Lab, Biochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt
dDepartment of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11754, Egypt
eChemistry Department, College of Science at Yanbu, Taibah University, Yanbu 46423, Saudi Arabia
fChemistry Department, College of Sciences, Taibah University, Al-Madina 30002, Saudi Arabia
gCenter of Excellence for Drug Preclinical Studies (CE-DPS), Pharmaceutical and Fermentation Industry Development Center, City of Scientific Research & Technological Applications (SRTA-city), New Borg El Arab, Alexandria, Egypt
First published on 5th June 2024
Correction for ‘Targeting EGFR/PI3K/AKT/mTOR signaling in lung and colon cancers: synthesis, antitumor evaluation of new 1,2,4-oxdiazoles tethered 1,2,3-triazoles’ by Mohammed Salah Ayoup et al., RSC Adv., 2024, 14, 16713–16726, https://doi.org/10.1039/D4RA02222J.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2024 |